IngredientsGinkgo biloba L. is one of the most unique plants that have ever grown on the planet — a member of the family Ginkgoaceae with no close living relatives. It is the oldest genus among existing seed plants and the only survivor of the family Ginkgoaceae, traceable back more than 200 million years to the fossils of the Permian period. It is a deciduous tree reaching 20–40 meters in height, native to eastern China, and is considered a "living fossil" since it probably originated approximately 200 million years ago.
The tree is commonly known as the maidenhair tree, a reference to the resemblance of its fan-shaped, bilobed leaves to the leaflets of maidenhair ferns. In Chinese traditional medicine, the seeds are referred to as bái guǒ (白果), meaning "white fruit." The standardized pharmaceutical extract derived from the dried leaves is most frequently designated EGb 761 (a registered trademark of Dr. Willmar Schwabe GmbH & Co KG, Karlsruhe, Germany), also marketed under trade names including Tanakan, Rokan, and Tebonin Forte.
Ginkgo biloba is a relict tree species showing high resistance to adverse biotic and abiotic environmental factors. Its fruits and leaves have high medicinal value due to the presence of flavonoids, terpene trilactones, and phenolic compounds. However, ginkgo seeds contain toxic and allergenic alkylphenols.
Ginkgo biloba is available commercially in several forms:
Ginkgo biloba was first recorded as a medicinal plant in the Chinese Materia Medica Shen Nong Ben Cao Jing approximately 2,000 years ago, and only the seeds were reported to be used as medicine. Preparations of Ginkgo biloba leaves have been used as remedies in China for more than 5,000 years, since the earliest origin of Chinese herbal medicine.
The employment of Ginkgo biloba in traditional Chinese medicine stretches back millennia, where ancient healers tapped into the power of the tree's seeds and leaves for an array of health advantages. Written records from these early periods indicate its use primarily for mitigating respiratory concerns like asthma and persistent coughs. Besides its respiratory applications, the Chinese acknowledged the potential of Ginkgo biloba seeds to tackle digestive issues and conditions related to bladder health.
In the 16th century, the polymath Li Shi-Zhen compiled extensive records of ginkgo's medicinal uses in the Ben Cao Gang Mu (Compendium of Materia Medica, 1596). In the Ben Cao Gang Mu, Li Shi-Zhen used the term "bai guo" (Ginkgo seed) to refer to Ginkgo biloba. In total, 17 traditional uses were reported in the book, including 8 for skin disorders such as chapped hands and feet, rosacea, patches and nodules on the face and scalp, genital ulcers, crab louse-induced itchiness, dog bite wound abscess, mastitis, and bullae or pustules. In the methods of preparation, Li Shi-Zhen mentioned applying the paste of raw ginkgo kernels to the affected area, or rubbing sliced-open raw kernels on it. The paste could be prepared by chewing, crushing, or crushing with wine.
In addition to its practical uses, Ginkgo was, and continues to be, considered a sacred tree in China, Japan, and Korea as part of different spiritual traditions, including Confucianism, Taoism, Buddhism, and Shintoism. Ginkgo trees are frequently found on the grounds of temples and shrines. Its seeds have been used as snacks and medical materials in Traditional Chinese Medicine, while over the last century its leaf extracts emerged as a source of rising pharmaceutical commerce related to brain health in Western medicine.
The advent of Ginkgo biloba in Western countries occurred much later, with its first documentation appearing in the 17th century by European botanists who began to take interest in its unique characteristics. Phytopharmaceutical extracts from the leaves of Ginkgo biloba have been applied to treat cerebrovascular and peripheral vascular diseases in many countries, such as Germany, France, Japan, and Korea since the 1960s. Extracts from leaves of the Ginkgo biloba tree have been developed in Germany since the 1960s. Today, Ginkgo leaf extracts belong to the most commonly used herbal medicines and are the subject of many scientific studies.
The chemical components of ginkgo leaves extract are counted by their hundreds; classes of compounds such as flavonoids (mostly glycosides of quercetin, kaempferol, and isorhamnetin) and terpenoids, among others, have been documented. The two pharmacologically defining compound classes are the flavonol glycosides and the terpene trilactones.
The principal effective component in Ginkgo biloba leaves is flavonoids, which comprise at least 14 different compounds, such as flavonols, flavones, flavanols, and biflavonoids. The extract contains 24% flavonol glycosides, 6% terpene lactones, and trace amounts of other substances including proanthocyanidins and organic acids. These flavonoids are potent free-radical scavengers and contribute significantly to ginkgo's antioxidant activity.
The terpene compounds are identified predominantly in Ginkgo biloba trees and include the diterpenes ginkgolides A, B, C, J, and M, and the sesquiterpene bilobalide. They constitute nearly 6–7% of EGb. The ginkgolides have six five-membered rings (three lactones, a tetrahydrofuran ring, and two carbocycles) and a tert-butyl group. Variations among ginkgolide subtypes are attributable to differences in the number and positioning of hydroxyl groups.
Since they share structural similarities with picrotoxinin (chloride channel blockers), ginkgolides and bilobalides act as potent, selective GABA receptor antagonists and attenuate inhibitory synaptic transmission in the adult CNS. However, the potent actions displayed by bilobalides are slightly weaker than those of ginkgolides.
The ginkgolides and bilobalide as components of EGb 761 are described in the literature to be bioavailable by up to 70–80%. The neuroprotective effects of these compounds are thus due to their ability to be absorbed and reach the CNS.
Structurally similar to the irritants in poison ivy, ginkgolic acids are the factors responsible for toxic effects of Ginkgo biloba extracts, including gastrointestinal disturbances, headaches, skin irritation, dermatitis, and edema. For this reason, the standardized pharmaceutical extract EGb 761 severely limits their concentration. EGb761 contains less than 5 parts per million (ppm, i.e., μg/g) of ginkgolic acids.
The European Pharmacopoeia requires that dried G. biloba leaf is to be extracted with 60% acetone (m/m) as primary extraction solvent, and the final product is adjusted to 22.0%–27.0% ginkgo flavonoids calculated as ginkgo flavone glycosides and 5.4%–6.6% terpene lactones consisting of 2.8%–3.4% ginkgolides A, B, C, and 2.6%–3.2% bilobalide, and contains less than 5 ppm ginkgolic acids. The US Pharmacopoeia specification for flavonol glycosides and ginkgolic acids is the same as the European, but the specification for terpene trilactones can range from 5.4%–12.0%. The Chinese Pharmacopoeia specifies only lower limits of at least 6% terpene trilactones and at least 24% flavonol glycosides with no upper limits.
The most commonly described mechanisms of action of ginkgo include anti-inflammatory, antioxidant, cerebral glucose utilization enhancement, reduced platelet aggregation, neurotransmitter regulation, and vasomotor effects.
The antioxidant activity of ginkgo leaves has been established as one possible mechanism for numerous pharmacological effects of the plant. This includes protection of neuronal and cardiovascular cells from reactive oxygen species (ROS)-mediated cell damage under ischemic conditions and other pathologies. The same mechanism also contributes to the potential antidiabetic effect of the plant, as diabetes pathology is associated with excessive oxidative stress.
The main mechanisms of action of Ginkgo biloba include vasoregulation (increased blood flow), platelet-activating factor antagonism, and prevention of membrane damage caused by free radicals — all activities that reduce tissue ischemia. Ginkgolide B is the most potent known naturally occurring inhibitor of platelet-activating factor and is a key mediator of ginkgo's anti-aggregatory and anti-inflammatory effects.
Ginkgo biloba displays myocardial suppressant and vasorelaxant activities ex vivo. It improves perfusion in different vascular beds without significantly affecting blood pressure and heart rate. In addition, it displays an acceptable safety profile, with most reported adverse reactions constituting rare occurrences. Collectively, Ginkgo biloba impacts cardiovascular physiology, improving hemodynamics and organ perfusion.
Following chronic treatment (100 mg/kg for 14 days in animal studies), EGb 761 significantly increased extracellular dopamine and noradrenaline levels in the prefrontal cortex, while 5-HT levels were unaffected. Chronic treatment with EGb 761 showed dose-dependent increases in frontocortical dopamine levels. The increase in dopamine levels was mostly caused by the flavonol glycosides and ginkgolide fractions, whereas bilobalide treatment was without effect. These data demonstrate that chronic treatment with EGb 761 increased dopaminergic transmission in the prefrontal cortex (PFC).
Ingredients of ginkgo leaves exert appreciable blood-brain barrier (BBB)-crossing efficacy and neuroprotective efficacy. These compounds have numerous pharmacological effects in the CNS, from specific action on receptors for neurotransmitters to general mechanisms of neuroprotection from ischemia-, β-amyloid-, and inflammation-induced injuries. EGb 761 has direct effects against necrosis and apoptosis of neurons and improves neural plasticity as evidenced in vestibular compensation.
This is the most extensively studied application of ginkgo biloba, and also the area with the most contested and mixed evidence base.
Large-scale prevention trials: The Ginkgo Evaluation of Memory (GEM) study was a randomized, double-blind, placebo-controlled clinical trial conducted in five academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6.1 years. Three thousand sixty-nine community volunteers aged 75 years or older with normal cognition (n=2,587) or mild cognitive impairment (MCI, n=482) were assessed every 6 months for incident dementia. In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or Alzheimer's disease incidence in elderly individuals with normal cognition or those with MCI.
A large, placebo-controlled, randomized clinical trial studying the well-characterized ginkgo product EGb-761 in more than 3,000 older adults found it ineffective in lowering the overall incidence of dementia and Alzheimer's disease. Further analysis of the same data also found ginkgo to be ineffective in slowing cognitive decline, lowering blood pressure, or reducing the incidence of hypertension.
Evidence in existing dementia and MCI: Findings are more nuanced in patients who already have cognitive impairment. A 2020 meta-analysis of 7 randomized controlled trials involving 939 patients with Alzheimer's disease found that those given Ginkgo biloba extract EGb-761 had some improvement in cognitive function. A 2016 systematic review and meta-analysis of 21 randomized controlled trials involving 2,608 participants concluded that Ginkgo biloba is potentially beneficial for improving cognitive function, activities of daily living, and global clinical assessment in people with mild cognitive impairment or Alzheimer's disease; however, because of small sample size, inconsistent findings, and methodological quality of studies included in the review, more research is needed to confirm effectiveness and safety.
An overview of ten systematic reviews found that medication with ginkgo biloba extracts showed improvement in cognition, neuropsychiatric symptoms, and daily activities, and the effect was dose-dependent. Efficacy was convincingly demonstrated only when a high daily dose of 240 mg was applied.
A systematic review and meta-analysis found that nine trials using the standardized extract EGb 761 met inclusion criteria, with trials of 12 to 52 weeks duration including 2,372 patients in total. In the meta-analysis, standardized mean differences in change scores for cognition were in favor of ginkgo compared to placebo, but did not show a statistically significant difference from placebo for activities in daily living. Heterogeneity among studies was high. For the Alzheimer's subgroup, the standardized mean differences for both activities of daily living and cognition were larger than for the whole group of dementias, with statistical superiority for ginkgo also for daily living outcomes.
A review of the evidence summarizes that EGb 761 has shown convincing results in improving cognitive function, neuropsychiatric symptoms, and reduction of caregiver stress. A randomized, double-blind, placebo-controlled, multicentric study (GuidAge), including French people with subjective memory deficit followed prospectively for more than five years, showed that EGb 761 treatment could not prevent dementia incidence. A post hoc analysis of a subgroup of people continuing EGb 761 for at least four years showed a significant reduction of dementia development (50% more than the placebo group), though methodological questions arose regarding these statistical models.
Overall assessment of evidence strength: There is no conclusive evidence that Ginkgo biloba is efficacious in preventing or slowing dementia or cognitive decline in healthy or mildly impaired older adults. There is clearer evidence to support the efficacy of ginkgo biloba extracts for MCI and existing dementia, whereas the question on efficacy to prevent cognitive decline is still open. GBEs seem to be generally safe. While the majority of synthesized clinical trials show that Ginkgo biloba has promising potential for the treatment of these conditions, more research is needed to determine optimal dosages, effective delivery methods, and appropriate pharmaceutical formulations.
There is evidence of efficacy for the standardized extract EGb 761 in the treatment of tinnitus from three trials in patients in whom tinnitus was the primary complaint. Supportive evidence comes from a further five trials in patients with age-associated cognitive impairment or dementia in whom tinnitus was present as a concomitant symptom. As yet, the efficacy of other ginkgo preparations has not been proven, which does not necessarily indicate ineffectiveness, but may be due to flawed clinical trials.
In one randomized, double-blind trial, patients with sub-chronic or chronic tinnitus were randomized to receive 120 mg EGb 761 or 600 mg pentoxifylline, each twice daily in a double-dummy fashion over a 12-week period. EGb 761 and pentoxifylline are both frequently prescribed for tinnitus treatment. For both treatment groups, significant improvements were observed in tinnitus loudness, annoyance, and overall suffering. There was no relevant difference between the two treatment groups with regard to tinnitus-related outcomes. EGb 761 and pentoxifylline were similarly effective. The incidence of adverse events was lower in the EGb 761 group.
A more recent exploratory study examined EGb 761 in chronic tinnitus: The primary objective of this multicentre, single-arm, open-label, exploratory clinical trial was to investigate whether comorbidities influence the treatment effect of EGb 761. Responder analyses required at least 30% score reduction in three out of four outcomes. At week 24, significant improvements were observed in all tinnitus-related outcomes compared to baseline. In subgroup analyses, patients with high baseline anxiety or stress as well as those with normacusis (normal hearing) improved more, whereas baseline depression had no influence. The overall response rate was 18.8%. The therapy appears to be particularly beneficial for patients with normal hearing and/or concomitant anxiety and/or stress.
Ginkgo biloba extract EGb 761 has been utilized extensively in the treatment of peripheral artery occlusive disease. However, its clinical benefit in this area remains uncertain.
An earlier meta-analysis offered modest support: results from twelve double-blind, randomized trials suggested that Ginkgo biloba extract is superior to placebo in the symptomatic treatment of intermittent claudication. However, the size of the overall treatment effect is modest and of uncertain clinical relevance. The overall increase in pain-free walking distance was 34 meters in favor of Ginkgo biloba — a modest effect of uncertain clinical relevance.
The more recent Cochrane review is less favorable: overall, there is no evidence that Ginkgo biloba has a clinically significant benefit for patients with peripheral arterial disease. Eleven trials involving 477 participants compared Ginkgo biloba with placebo and assessed the absolute claudication distance (ACD). Following treatment with Ginkgo biloba at the end of the study, the ACD increased with an overall effect size of 3.57 kilocalories (CI −0.10 to 7.23, P = 0.06) compared with placebo. This translates to an increase of just 64.5 meters (CI −1.8 to 130.7) on a flat treadmill. Publication bias leading to missing data or "negative" trials is likely to have inflated the effect size. Before Ginkgo biloba can be advised for use in clinical practice, further research would be required. However, given the small absolute summary effect in the reported trials, it is unlikely that the effect of Ginkgo biloba will ever be clinically relevant.
One substantial, well-designed double-blind, placebo-controlled study found evidence that ginkgo extract taken at a dose of 240 mg or 480 mg daily may help anxiety. Additionally, it has been discovered that people with mental impairment who take EGb 761 have less anxiety. This evidence base is currently limited and should be considered preliminary.
EGb 761 is able to modify blood rheology to enhance blood flow as well as to promote neuroprotection and modulate neurotransmission; the mechanism of action behind these therapeutic benefits is complex. Most clinical data on the efficacy of Ginkgo biloba is from clinical studies, with few results from healthy subjects. Available research provides a comprehensive review of the mechanisms underlying the known beneficial cardiovascular activities of Ginkgo biloba and its main compounds. In the future, better controlled clinical studies should be performed in order to identify the target populations who could benefit the most with pharmacotherapeutic interventions involving this plant.
Ginkgo biloba extract EGb 761 has been utilized in the treatment of vestibular and non-vestibular vertigo in addition to the areas described above. EGb 761 and its components have been studied in pre-clinical and clinical settings for their beneficial effects on a wide range of pathological states, from vascular problems and ischemic stroke to diabetes-related health complications to neurodegenerative conditions leading to cognitive decline and dementia, including Alzheimer's disease. Evidence in many of these secondary areas remains preliminary or largely preclinical.
Ginkgo biloba extract administration is via the oral route. Most ginkgo extract is in the form of EGb 761, standardized to include 6% terpenoids and 24% flavonoid glycosides. Standard dosages of EGb 761 used in most studies and recommended by manufacturers are 40 mg three times per day, or 80 mg twice daily (totaling 120 mg/day).
Specific dosages reported across clinical trials include:
In general, Ginkgo biloba is safe and well-tolerated. Compared with placebo, overall adverse events and serious adverse events were at the same level as placebo in systematic review data, with fewer adverse events in favor of ginkgo biloba extract in the subgroup of Alzheimer's disease patients, and fewer incidences in vertigo, tinnitus, angina pectoris, and headache. Common mild adverse effects include gastrointestinal upset, headaches, and dizziness.
The interaction between ginkgo biloba and anticoagulant or antiplatelet drugs is one of the most clinically discussed safety issues. The evidence is notably mixed. Although the potential bleeding risk of Ginkgo biloba has been much discussed in the literature, initial concerns were based on case reports describing a temporal association between ginkgo use and bleeding events. Some evaluations of randomized controlled trials have not found a higher bleeding risk. A systematic review and meta-analysis of 18 randomized controlled trials examined the impact of ginkgo on hemostasis parameters and found a significant reduction in blood viscosity; however, there were no effects on other factors, such as ADP-induced platelet aggregation, fibrinogen concentration, activated partial thromboplastin time, and prothrombin time.
Nonetheless, institutional bodies flag this interaction: the NCCIH notes that taking Ginkgo biloba with warfarin is associated with increased risk for major bleeding events compared to warfarin alone. Concomitant use of Ginkgo biloba preparations and efavirenz (a non-nucleoside reverse transcriptase inhibitor) is not recommended. Ginkgo may increase the risk of bleeding in people who are taking anticoagulant drugs such as warfarin.
A large hospital-based observational study provided further real-world data: out of 2,647 prescriptions meeting inclusion criteria, 342 exhibited drug interactions with a prevalence rate of 12.94%. Ginkgo biloba extract frequently interacts with antiplatelets, anticoagulants, and nonsteroidal anti-inflammatory drugs, with clopidogrel and aspirin exhibiting the highest prevalence rates at 2.61% each. However, interactions with anticoagulants including direct oral anticoagulants and acenocoumarol were not statistically significant in this analysis. Significant correlations were found between Ginkgo biloba extract drug interactions and bleeding risk (OR: 1.08, p < 0.001) and abnormal coagulation (OR: 1.49, p < 0.001).
Ginkgolic acids, structurally similar to the irritants in poison ivy, are the factors responsible for toxic effects of Ginkgo biloba extracts, including gastrointestinal disturbances, headaches, skin irritation, dermatitis, and edema. Standardized leaf extracts mitigate this risk: EGb 761 contains less than 5 parts per million (ppm) of ginkgolic acids.
The seeds pose a separate, more severe toxicity risk. Fresh ginkgo seeds are toxic when consumed orally, and serious side effects — including seizures and death — have occurred in people who consumed raw ginkgo seeds or the crude ginkgo plant. Roasted ginkgo seeds can also cause adverse reactions. This is a distinct hazard from ginkgo leaf extract supplements. The neurotoxic compound in ginkgo seeds primarily responsible for seizures is ginkgotoxin (4-O-methylpyridoxine), which acts as an antagonist of vitamin B6 and can precipitate seizures, particularly in children and with large quantities.
Ginkgo may be unsafe for use during pregnancy. It might cause early labor or extra bleeding during delivery if used near that time. Little is known about whether it's safe to use ginkgo while breastfeeding.
Concomitant use of Ginkgo biloba preparations and efavirenz (a non-nucleoside reverse transcriptase inhibitor) is not recommended. This interaction relates to ginkgo's induction of cytochrome P450 enzymes, particularly CYP3A4, which can reduce plasma concentrations of co-administered drugs that rely on this metabolic pathway.
Even two high-quality extracts complying with the same pharmacopoeia guideline can be disparate in nature. For instance, a range of 22%–27% flavone glycosides is relatively broad: if extract A contains 22% and extract B contains 27%, extract B could contain almost 23% more of that compound class compared to extract A. This variability between commercial products has important implications for the reliability of dosing and predicted efficacy across non-standardized preparations.
Health conditions that Ginkgo biloba may help support.
Ginkgo biloba extract (standardized as EGb 761) has well-documented antioxidant properties supported by both mechanistic and human clinical evidence. Its flavonoid glycosides and terpene lactones scavenge reactive oxygen species (ROS), upregulate endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase), and activate the Nrf2 pathway. Clinical trials in humans—including patients with mild cognitive impairment—have recorded measurable increases in blood antioxidant biomarkers following EGb 761 administration. The antioxidant mechanism is considered a key contributor to its documented benefits in cerebrovascular and neurodegenerative conditions.
Ginkgo biloba (EGb 761 standardized extract) has shown anxiolytic activity in clinical trials, primarily in patients with cognitive impairment, where it reduced anxiety and depression symptoms significantly vs. placebo. Preclinical studies in rodents demonstrate anxiolytic effects via ginkgolide-A. It modulates monoaminergic neurotransmission, inhibits norepinephrine reuptake, and has anti-inflammatory effects.
Ginkgo biloba standardized extract (EGb 761) improves arterial endothelial function, reduces platelet-activating factor activity, inhibits leukocyte adhesion to injured arteries, and improves microcirculation. Controlled clinical trials demonstrate efficacy in peripheral arterial disease. A 2025 PubMed-indexed review confirmed its anti-inflammatory vascular activity as an anti-atherosclerotic nutraceutical.
Ginkgo biloba extract inhibits platelet-activating factor (PAF), a potent trigger of asthmatic bronchoconstriction, via its ginkgolide B constituent. It has been studied in at least one RCT with asthma patients and inhibits PAF-induced bronchoconstriction and airway inflammation. A murine study confirmed ginkgolide B suppressed Th2 cytokines and eosinophilia via ERK/MAPK pathway inhibition.
Ginkgo biloba has been evaluated in multiple RCTs for ADHD in children, with results showing significant reductions in inattention and ADHD rating scale scores compared to placebo, though it is less effective than methylphenidate. A 2025 systematic review identified three qualifying RCTs, one of which (Shakibaei et al.) found 93.5% vs 58.6% response rates in treated vs placebo groups.
Ginkgo biloba leaf extract has established neuroprotective and microcirculation-enhancing properties relevant to Bell's palsy, which involves ischemic/inflammatory compression of the facial nerve. Life Extension's Bell's palsy protocol identifies ginkgo as potentially beneficial for nerve cell function. A study referenced in PubMed (PMID 23021527) evaluated ginkgo's effect on recovery after facial nerve injury.
Ginkgo biloba contains ginkgolides that inhibit platelet-activating factor (PAF), reducing platelet aggregation. A 2025 PLoS ONE analysis found ginkgo biloba interactions were significantly associated with bleeding risk (OR 1.08, p<0.001) and a large chart review (n=807,399) found its combination with warfarin increases major bleeding risk. Evidence on standalone antiplatelet efficacy in controlled trials is mixed.
Ginkgo biloba extract has been examined for cardiovascular effects including blood pressure modulation, largely through its vasodilatory and PAF-antagonist mechanisms. Some clinical evidence suggests modest effects on vascular tone. However, the evidence base for blood pressure specifically is not conclusive, and ginkgo is not recognized by major guidelines as a blood pressure intervention.
Ginkgo biloba is one of the most extensively studied herbs for cognitive function, with a long history of use in Traditional Chinese Medicine for mental clarity. Standardized extracts (24% flavone glycosides, 6% terpene lactones) enhance cerebral blood flow, inhibit platelet-activating factor, and act as antioxidants. Multiple RCTs and meta-analyses support improvements in attention, memory, and processing speed in adults with cognitive impairment and age-related cognitive decline.
Ginkgo biloba extract is incorporated into validated oral anti-cellulite supplements and topical formulations. Its dimeric flavonoids inhibit phosphodiesterase, enhancing cAMP-mediated lipolysis and microvascular perfusion. A US patent specifically claims Ginkgo biloba dimeric flavonoids for cellulite treatment and a retrospective clinical trial (21 women, 90 days) showed anti-cellulite benefit.
Ginkgo biloba extract has well-documented effects on cerebral blood flow and mitochondrial function that may contribute to reduced mental fatigue. It is among the most extensively studied herbal supplements with numerous clinical trials showing improvements in cognitive performance, mental energy, and fatigue in both healthy adults and those with cognitive decline.
A 2022 systematic review and meta-analysis of 17 RCTs (1,104 participants) found that ginkgo biloba leaf extract (GBLE) significantly reduced serum CRP and IL-6 levels. Effects on CRP were strongest at baseline levels ≥3 mg/L and doses <500 mg/day. Evidence is promising but heterogeneous, with variability in study design and populations limiting firm conclusions.
Ginkgo biloba extract (GBE) has robust clinical evidence for improving blood flow across multiple vascular beds, including coronary, cerebral, cutaneous, and peripheral circulation. Multiple RCTs in CAD patients and healthy elderly adults demonstrate increased LAD blood flow and improved endothelium-dependent vasodilation. Nine double-blind RCTs in peripheral arterial insufficiency showed significantly increased pain-free and maximum walking distances alongside measurable plethysmographic blood-flow improvements.
Ginkgo biloba extract (EGb 761) has been extensively studied in human clinical trials for cognitive decline and healthy aging, making it one of the most researched botanical supplements in this domain. Evidence is mixed: large RCTs found no benefit for preventing dementia or slowing cognitive decline in cognitively normal older adults, while shorter RCTs at 240 mg/day show modest improvements in cognition and neuropsychiatric symptoms in mild cognitive impairment (MCI). An overview of ten systematic reviews concluded there is clear evidence supporting efficacy in MCI and dementia treatment, but the prevention question remains unresolved.
Ginkgo biloba extract (EGb761) has been evaluated as an adjunct for depression in multiple trials. A 2024 systematic review and meta-analysis (21 studies, n=2,074 patients) found significantly better Hamilton Depression Scale scores in ginkgo-treated patients at 4, 6, and 8 weeks versus controls. It is most studied as an adjunct in elderly and post-stroke depression.
A 2021 systematic review of 5 RCTs (475 participants) concluded that ginkgo biloba has limited positive effects on sexual function overall. Evidence for male erectile function specifically is weak, with preclinical data showing benefit after nerve injury but human trial results being inconsistent. The overall clinical evidence does not currently support ginkgo as an effective monotherapy for erectile dysfunction.
Ginkgo biloba extract (GBE) improves ocular microcirculation and has been studied for visual fatigue and glaucomatous visual field damage. A retrospective analysis (PMC3429325, n=332 patients) found GBE improved visual function in normal-tension glaucoma patients versus controls. Its flavone glycosides and terpenelactones support blood flow to the optic nerve and retina, which is relevant to fatigue from prolonged screen use.
Ginkgo biloba has been studied in pediatric ADHD with several RCTs and open-label trials showing improvements in attention and ADHD symptoms. A 2023 systematic review of herbal medicines for pediatric ADHD found several pieces of evidence supporting the efficacy of Ginkgo biloba. However, NCCIH notes current evidence is insufficient to formally recommend it for ADHD.
Ginkgo biloba leaf extract is among the most studied herbal nootropics, with multiple RCTs and meta-analyses demonstrating improvements in memory, attention, and processing speed, particularly in individuals with age-related cognitive decline. Its mechanisms include enhanced cerebral blood flow, antioxidant action, and inhibition of platelet-activating factor via ginkgolide B. German Commission E and ESCOP have approved standardized extract for cognitive disorders.
Ginkgo biloba extract (GBE) contains flavonoids and terpenoids with antioxidant and vasoactive properties that improve retinal and optic nerve blood flow. A Korean RCT (n=30, normal tension glaucoma) found 80 mg GBE twice daily significantly improved retinal blood flow vs. placebo. Small clinical trials also showed modest improvements in AMD-related vision and glaucoma-associated visual field damage.
Ginkgo biloba extract (EGb 761) has been studied in multiple clinical trials for glaucoma, particularly normal-tension glaucoma. Its standardized extract enhances ocular microcirculation, improves peripapillary blood flow, and has antioxidant properties relevant to optic nerve protection. A 2003 RCT found 120 mg/day improved visual field loss in low-pressure glaucoma patients.
Ginkgolide B, a terpene constituent of ginkgo biloba, has been studied as a PAF antagonist for migraine prophylaxis, particularly in young patients and women with migraine with aura. Small clinical trials show reductions in attack frequency and aura duration. Evidence is preliminary, with no large RCTs examining ginkgo as a monotherapy.
Ginkgo biloba has been used in Traditional Chinese Medicine for thousands of years and is extensively studied for cognitive aging. A PubMed narrative review (2022) synthesizes evidence linking ginkgo to memory improvement, cognitive protection, antioxidant effects, and cardiovascular support. Multiple RCTs in older adults demonstrate benefits for cognitive function and quality of life.
Ginkgo biloba extract (GBE) has been used in traditional Chinese medicine for vision and is recognized in ocular health for its antioxidant, anti-inflammatory, and vasodilatory properties that improve microcirculation in retinal capillaries. A randomized placebo-controlled trial of normal tension glaucoma patients showed improvement in pre-existing visual field damage with GBE. Scientific reviews confirm GBE's role in several degenerative eye diseases including AMD, though evidence is described as promising but not yet conclusive.
Ginkgo biloba (standardized extract EGb 761) is the most-studied herbal supplement for tinnitus and hearing loss. It is believed to improve inner-ear and cerebral blood circulation and protect against free radicals. European and American otolaryngology guidelines have recommended it for reducing tinnitus annoyance. Evidence from randomized controlled trials is mixed but a systematic review of five RCTs concluded standardized extract is an evidence-based treatment option for tinnitus.
Ginkgo biloba extract (GBE) has documented cardiovascular-relevant mechanisms — including vasorelaxation, inhibition of platelet aggregation, and improved coronary perfusion — supported by both laboratory and clinical data. However, the largest high-quality randomized trial (GEM Study, n=3,069) found no reduction in cardiovascular events or CVD mortality. Evidence is mixed overall, with clinical benefit most consistently demonstrated for peripheral arterial disease (intermittent claudication) rather than primary cardiac endpoints.
Ginkgo biloba leaf extract is one of the most extensively studied herbal nootropics, with a centuries-long history in traditional Chinese medicine. Its standardized extract (EGb 761) has been evaluated in numerous RCTs showing improvements in memory, attention, and processing speed, particularly in those with cognitive impairment. It acts as a cerebral vasodilator, antioxidant, and inhibitor of platelet-activating factor.
Ginkgo biloba has been used in TCM and has been clinically studied for sexual function, particularly in men with SSRI-induced sexual dysfunction. Multiple studies suggest it enhances penile blood flow via nitric oxide and platelet-activating factor antagonism. Clinical evidence is modest but consistent for pro-sexual effects in men.
Ginkgo biloba has been evaluated in clinical studies for lymphedema, with a study of 48 patients using Ginkor Fort (ginkgo extract) showing statistically significant improvement in limb heaviness in breast cancer-related arm lymphedema. It was also part of the Horsechestnut Complex used in the lymphoscintigraphy trial demonstrating significantly improved lymphatic drainage rates. Its ginkgolides and flavonoids protect capillary collagen integrity and improve microcirculation.
Ginkgo biloba extract contains flavone glycosides and terpene lactones (ginkgolides, bilobalide) with antioxidant and circulatory-enhancing properties relevant to AMD. A 6-month double-blind, placebo-controlled trial in 20 AMD patients (160 mg/day) reported improved visual acuity in the ginkgo group versus placebo. A Cochrane review identified only two small trials, concluding evidence is promising but insufficient to make definitive recommendations.
Ginkgo biloba extract (EGb) is one of the most extensively studied botanicals for memory and cognitive function, used traditionally in China and now globally. Evidence from RCTs is mixed: some trials in elderly patients with mild-to-moderate cognitive impairment show improvements in memory and cognitive scales, while the large GEM trial (n=3,069) found no significant effect in healthy older adults. It is best supported in populations with existing cognitive decline.
Ginkgo biloba leaf extract is one of the most studied herbal preparations for cognitive function, with traditional Chinese medicine use spanning centuries. Clinical trials show modest but consistent improvements in attention, working memory, and processing speed in healthy adults and those with age-related cognitive decline.
Ginkgo biloba, primarily via its terpene constituent ginkgolide B, has been studied for migraine with aura prophylaxis. Open clinical trials and preliminary studies suggest potential benefit, particularly for reducing aura frequency and duration. The 2019 PMC integrative migraine review identified positive results from older ginkgolide B studies.
Ginkgo biloba is one of the most researched herbal medicines for cognitive health, used in Traditional Chinese Medicine for thousands of years. Standardized extract EGb 761 improves cerebral blood flow, has potent antioxidant properties protecting brain cells, and shows moderate evidence for managing dementia symptoms.
Ginkgo biloba extract (EGb 761) contains ginkgolides, bilobalide, and flavone glycosides that improve peripheral nerve blood flow, reduce oxidative stress, and promote nerve cell survival. Listed in authoritative peripheral neuropathy evidence databases alongside ALC and methylcobalamin, it has traditional use in Chinese medicine for nerve conditions dating to the Ming Dynasty and scientific evidence for microvascular and neuroprotective benefits.
Ginkgo biloba's standardized extract (EGb761) modulates BDNF, stimulates Akt/mTOR neuroplasticity pathways, promotes neurite outgrowth, and improves cerebral microvascular function. A peer-reviewed 2017 Neural Plasticity review identified in vitro, in vivo, and clinical evidence for BDNF modulation. It has been used in Traditional Chinese Medicine for centuries.
Ginkgo biloba extract inhibits monoamine oxidase A and B, reducing catecholamine and serotonin degradation, and upregulates muscarinic acetylcholine receptors. Cochrane-referenced meta-analyses confirm cognitive and memory benefits in dementia, consistent with monoamine and cholinergic neurotransmitter support. Approved by German Commission E and WHO for age-related cognitive decline.
Ginkgo biloba extract (EGb761) has been studied in both animal models and clinical settings for Parkinson's disease. Animal studies consistently show neuroprotection of dopaminergic neurons via MAO-B inhibition and antioxidant activity. A clinical RCT assessed its efficacy in drug-induced parkinsonism. A 2013 systematic review of 10 controlled animal studies confirmed neuroprotective effects.
Ginkgo biloba extract has been evaluated in RCTs for PMS, with studies finding reductions in congestive and mood-related PMS symptoms. A 2009 RCT using standardised EGb 761 extract administered from day 16 of the cycle through day 5 of the next cycle showed significant reductions in PMS symptom severity versus placebo.
A double-blind, placebo-controlled RCT (Muir et al., Vasc Med 2002, PMID 12710841) found standardized ginkgo biloba extract at 360 mg/day for 10 weeks reduced Raynaud's attacks per week by 56% versus 27% for placebo in primary Raynaud's patients. Ginkgo's platelet-activating factor antagonism and vasodilatory mechanisms are proposed to attenuate episodic digital vasospasm. A Korean comparative RCT (KOARA study) also evaluated ginkgo against nifedipine for primary Raynaud's. It is the best-researched herbal remedy for Raynaud's according to Scleroderma & Raynaud's UK.
Ginkgo biloba extract has been used for peripheral vascular disorders including chronic venous insufficiency related to spider veins. Its ginkgolides and bilobalide exert vasodilatory, antioxidant, anti-inflammatory, and PAF-inhibitory effects. Pilot studies support its use in chronic venous disease, and it is commonly referenced alongside horse chestnut and bilberry for spider vein management.
Ginkgo biloba, particularly the standardized extract EGb 761, is the most extensively studied botanical for tinnitus. A 2011 systematic review found evidence of efficacy for EGb 761 from three RCTs in patients with primary tinnitus. However, a 2022 Cochrane review concluded that current evidence does not demonstrate benefit over placebo, and major guidelines (AAO-HNS, European Multidisciplinary) now recommend against its use. The mixed evidence base is partly attributed to differences in preparation quality.
Standardized Ginkgo biloba extract EGb 761 has demonstrated efficacy for vertigo and balance disorders in multiple randomized controlled trials and a 2023 meta-analysis. It improves vestibular compensation, reduces dizziness severity, and enhances balance training outcomes in age-related vestibular dysfunction. A 12-week multicenter RCT in 120 patients aged 60+ found clinically relevant improvement in vertigo and dizziness when EGb 761 was combined with balance training.
Ginkgo biloba has multiple double-blind, placebo-controlled clinical trial evidence in vitiligo. A 2003 RCT showed 40 mg three times daily for 6 months arrested disease spread in 20/25 active-group patients and induced marked repigmentation in 10. A 2011 open-label pilot trial confirmed halting of progression and 15% average VASI improvement at 12 weeks.
Ginkgo biloba has a long history in Traditional Chinese Medicine for improving vitality and circulation. Some research has explored its effects on exercise performance via improved blood flow and oxygen delivery, but clinical RCTs in athletic populations have produced inconsistent results. Evidence for athletic performance specifically is weak.
Ginkgo biloba is traditionally used for cognitive support and circulation enhancement, addressing brain fog, memory decline, and mood disturbances common in menopause. Listed in botanical reviews as used for menopausal cognitive and mood symptoms. Evidence is primarily for general cognitive and circulatory benefits with indirect application to menopause.
Ginkgo biloba has a long history of use in traditional Chinese medicine for supporting mental vitality, clarity, and emotional wellbeing across seasonal transitions. Modern interest stems from its monoamine-modulating properties and neuroprotective effects. However, dedicated clinical trials for seasonal mood support or seasonal affective disorder specifically are lacking.
Ginkgo biloba leaf extracts contain flavonoids and terpene lactones with immunomodulatory and limited antiviral properties. Traditional use in Chinese medicine for respiratory conditions spans centuries. Some in vitro studies show activity against influenza and HIV, but clinical evidence for viral immune response specifically is limited.
Body systems that Ginkgo biloba may help support.
Go back